CDK4/6 inhibitors in breast cancer - from in  vitro models to clinical trials.

Conclusion: CDK4/6 inhibitors are highly specific making them a safe and viable therapeutic for BC and there is increasing evidence of their potential to improve survival, even in the metastatic setting. Although a number of trials have demonstrated this, as a lone therapy or in combination, optimisation of treatment scheduling are still required in further clinical investigations.
PMID: 31671026 [PubMed - as supplied by publisher]

Source: Acta Oncologica - October 30, 2019 Category: Cancer & Oncology Authors: Saleh L, Wilson C, Holen I Tags: Acta Oncol Source Type: research